-
-
-
-
-
-
-
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
-
-
-
-
-
-
-
Myriad Genetics secures $200 million credit facility from OrbiMed
-
-
-
-
-
-
-
Myriad Genetics (MYGN) Reports In-Line Q4 EPS
-
-
-
-
-
-
-
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance
-
-
-
-
-
-
-
Wells Fargo Offers 10 High-Conviction Long/Short Ideas for Q4, Comments on tesla (TSLA): 'We see declining delivery growth'
-
-
-
-
-
-
-
Myriad Genetics (MYGN) PT Raised to $28 at Raymond James
-
-
-
-
-
-
-
Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

